TW200730539A - Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 - Google Patents

Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1

Info

Publication number
TW200730539A
TW200730539A TW095144416A TW95144416A TW200730539A TW 200730539 A TW200730539 A TW 200730539A TW 095144416 A TW095144416 A TW 095144416A TW 95144416 A TW95144416 A TW 95144416A TW 200730539 A TW200730539 A TW 200730539A
Authority
TW
Taiwan
Prior art keywords
dab
noncompetitive
relates
domain antibody
receptor type
Prior art date
Application number
TW095144416A
Other languages
English (en)
Chinese (zh)
Inventor
Philip D Drew
Wildt Rudolf M T De
Ian M Tomlinson
Amrik Basran
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of TW200730539A publication Critical patent/TW200730539A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095144416A 2005-12-01 2006-11-30 Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 TW200730539A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74206205P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
TW200730539A true TW200730539A (en) 2007-08-16

Family

ID=37885775

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095144416A TW200730539A (en) 2005-12-01 2006-11-30 Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1

Country Status (14)

Country Link
US (1) US20090155283A1 (enExample)
EP (1) EP1957536A2 (enExample)
JP (1) JP2009519011A (enExample)
KR (1) KR20080077238A (enExample)
CN (1) CN101454344A (enExample)
AU (1) AU2006321364B2 (enExample)
BR (1) BRPI0619225A2 (enExample)
CA (1) CA2632866A1 (enExample)
CR (1) CR10022A (enExample)
EA (1) EA200801170A1 (enExample)
MA (1) MA30300B1 (enExample)
NO (1) NO20082215L (enExample)
TW (1) TW200730539A (enExample)
WO (1) WO2007063308A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4955185B2 (ja) 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
SG177601A1 (en) * 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
US20110082055A1 (en) * 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
DK2478137T3 (da) * 2009-09-18 2017-11-27 Codexis Inc Reduceret kodonmutagenese
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US20130149312A1 (en) * 2010-04-16 2013-06-13 Mcmaster University Compositions and methods for treating copd exacerbation
US20140112929A1 (en) * 2011-06-17 2014-04-24 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP2974737B1 (en) 2011-06-23 2025-10-22 Ablynx N.V. Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EA027160B1 (ru) * 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
CA2948945C (en) 2014-05-16 2023-08-08 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL295534B2 (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable sites
NO2768984T3 (enExample) 2015-11-12 2018-06-09
US11142569B2 (en) 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CA3029133C (en) 2016-06-23 2024-04-30 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
KR20240018673A (ko) 2016-11-28 2024-02-13 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
KR102533814B1 (ko) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
SG11201906264YA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
EP3602056A1 (en) 2017-03-31 2020-02-05 Ablynx N.V. Improved immunogenicity assays
TWI818934B (zh) 2017-11-28 2023-10-21 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
JP7414736B2 (ja) 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
EP3802831A4 (en) * 2018-05-30 2022-07-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
CN109336977A (zh) * 2018-10-11 2019-02-15 暨南大学 肿瘤干细胞标志分子EpCAM的结合蛋白及其应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US3907502A (en) * 1973-12-11 1975-09-23 Miless L Brink Method for identifying Bence Jones proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ATE102631T1 (de) * 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6451983B2 (en) * 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
OA10149A (en) * 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
EP0603194A4 (en) * 1991-07-05 1994-12-07 Seragen Inc TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR TARGETED MOLECULES FOR TREATING INFLAMMABLE ARTHRITIS.
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
DK0706799T3 (da) * 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US5664034A (en) * 1996-05-21 1997-09-02 Lucent Technologies Inc. Lightwave communication monitoring switch
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6777534B1 (en) * 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US20020192211A1 (en) * 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030175271A1 (en) * 1998-05-20 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. VEGF activity inhibitor
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
DE69926536T3 (de) * 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
SK16522001A3 (sk) * 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
EP1183352A1 (en) * 1999-05-20 2002-03-06 Scios Inc. Vascular endothelial growth factor variants
JP4981229B2 (ja) * 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
JP2003528632A (ja) * 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
WO2001089549A2 (en) * 2000-05-22 2001-11-29 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
DE10038624C2 (de) * 2000-08-03 2002-11-21 Broekelmann Aluminium F W Wärmeübertragungsrohr mit gedrallten Innenrippen
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
RU2003134180A (ru) * 2001-05-08 2005-02-10 Мерк Патент ГмбХ (DE) Комбинированная терапия, использующая антитела к egfr и антигормональные средства
BRPI0210405B8 (pt) * 2001-06-13 2021-05-25 Genmab As anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
WO2003014159A1 (en) * 2001-08-03 2003-02-20 Commonwealth Scientific And Industrial Research Organisation Methods of screening based on the egf receptor crystal structure
JP2005507659A (ja) * 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
AU2003209446B2 (en) * 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
NZ566539A (en) * 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
CN104059147A (zh) * 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
UA84024C2 (ru) * 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) * 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
AU2005206536B2 (en) * 2004-01-16 2010-09-02 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses

Also Published As

Publication number Publication date
WO2007063308A3 (en) 2007-09-20
CA2632866A1 (en) 2007-06-07
AU2006321364A1 (en) 2007-06-07
NO20082215L (no) 2008-08-14
WO2007063308A2 (en) 2007-06-07
MA30300B1 (fr) 2009-04-01
CR10022A (es) 2008-09-22
KR20080077238A (ko) 2008-08-21
AU2006321364B2 (en) 2011-11-10
JP2009519011A (ja) 2009-05-14
CN101454344A (zh) 2009-06-10
EA200801170A1 (ru) 2008-12-30
BRPI0619225A2 (pt) 2017-11-07
EP1957536A2 (en) 2008-08-20
US20090155283A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
TW200730539A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
TW200736276A (en) Competitive domain antibody formats that bind interleukin 1 receptor type 1
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
EP2371390A3 (en) Antagonists and methods of use therefor
EA200800696A1 (ru) Полипептиды и антитела
MY162624A (en) Antibodies directed to her-3 and uses thereof
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2008113515A3 (en) huTNFR1 SELECTIVE ANTAGONISTS
WO2025038726A3 (en) Interleukin 21 variants
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
PL1960427T3 (pl) Multimeryczne polipeptydy receptora Fc
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
ATE471945T1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
WO2003033665A3 (en) Secreted protein, ztnf9
ATE442444T1 (de) Glykosylphosphatidylinositolhaltige polypeptide
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
BRPI0516260A (pt) antagonista de fator de necrose tumoral 1, ligante, monÈmero de anticorpo de domìnio (dab), ácido nucleico, vetor, célula hospedeira, métodos para produzir um polipeptìdeo, um monÈmero de dab, um ligante multiespecìfico, e um formato de anticorpo, e para tratar, suprimir ou prevenir uma doença, composição, uso de um antagonista, formato de anticorpo, polipeptìdeo, e, anticorpo ou fragmento de ligação de antìgeno do mesmo
EP2062920A3 (en) Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
WO2023154785A3 (en) Il-2 trap molecules
WO2005058957A3 (en) Ztnf 12, a tumor necrosis factor